DR-510

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameDR-510

Drug Alias NameDR-510

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3CD3 T-cell engagersAnti-Epidermal growth factor receptor erbB1

TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesZhejiang Doer Biologics Corp

China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Doer Biologics Corp

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A